GRAIL: A $40M Bet Gone South (Naturally)

by

So, Baker Bros. Advisors dropped nearly $40 million on GRAIL (GRAL 17.07%) last quarter. Forty. Million. Let’s just pause for a moment and appreciate the sheer… optimism. Or, you know, the desperate need to deploy capital. I’m leaning towards the latter. They snagged 455,208 shares, which, in the grand scheme of things, isn’t nothing. But it’s also… a lot to hang on a company whose entire premise is detecting cancer before it’s actively trying to kill you. It’s a bit like betting on preventative measures. How very… responsible of them. And now, the stock has decided to stage a dramatic exit, plummeting over 50%. Predictable, really.

Let’s Dissect This, Shall We?

The SEC filing from February 17th, 2026, revealed this little spending spree. An increase of 455,208 shares. The estimated value? $39.33 million. The position, at quarter-end, had ballooned by $82.09 million, thanks to both the added shares and, briefly, the stock price cooperating. It represents roughly 1% of their assets. Which is… a significant 1%. Like, “we really, really believe in this” kind of 1%. Or, “we’ve already told everyone we believe in this, so we’re committed now,” which is often the same thing.

The Usual Suspects

  • Top five holdings after the quarter:
    • NASDAQ: INCY: $3.04 billion (17.8% of AUM)
    • NASDAQ: ONC: $2.67 billion (15.7% of AUM)
    • NASDAQ: MDGL: $1.25 billion (7.3% of AUM)
    • NASDAQ: INSM: $1.15 billion (6.7% of AUM)
    • NASDAQ: ACAD: $1.15 billion (6.7% of AUM)
  • As of February 23, 2026, shares of GRAIL were trading at $42.22. Up 4% year-over-year. Which is… a participation trophy. The S&P 500, meanwhile, was enjoying a lovely 13% gain. See? Optimism. It’s contagious.

The Pitch (Because There’s Always a Pitch)

Metric Value
Market capitalization $1.6 billion
Revenue (TTM) $141.83 million
Net income (TTM) ($406.24 million)
Price (as of February 17, 2026) $42.22

The Story They’re Selling

  • GRAIL, you see, is all about early cancer detection. Galleri, their flagship test, and DAC are supposed to be game-changers. They’re expanding into minimal residual disease and post-diagnostic testing, which sounds… ambitious.
  • They make money selling tests to healthcare providers. Proprietary biotechnology platforms, naturally. It’s always proprietary.
  • Their target audience? Over-50s, healthcare systems, and anyone else who might be persuaded that preventative measures are worth the cost. Which, let’s be honest, is a pretty broad demographic.

Basically, they’re trying to solve a really big problem with really complicated technology. Noble, I suppose. And potentially lucrative. If it works. Which is a very big “if.”

What Does This Mean For Us? (And By “Us” I Mean Anyone Watching This Train Wreck)

This, my friends, is textbook biotech volatility. A company can pump up revenue, hoard nearly a billion dollars in cash, and still get eviscerated because a clinical trial doesn’t hit a statistical benchmark. It’s… poetic, really.

GRAIL’s fourth-quarter revenue did rise 14% to $43.6 million, and full-year revenue climbed 17% to $147.2 million. U.S. Galleri revenue reached $136.8 million, up 26%. They sold over 185,000 Galleri tests in 2025 and ended the year with $904.4 million in cash. Enough to fund operations into 2030, they claim. Which is… reassuring. Until it isn’t.

The NHS-Galleri trial, however, didn’t achieve a statistically significant reduction in Stage III to IV cancers. Improvements in earlier-stage detection? Sure. But nuance rarely survives a stock market correction. And shares have plummeted nearly 60% since Thursday. Predictable. Absolutely predictable.

Within a portfolio brimming with oncology and biotech giants, a 1% allocation is a calculated gamble. Long-term investors should keep an eye on regulatory approval, commercial adoption, and cash burn. If Galleri becomes standard care, today’s collapse might seem like a blip. If not? Well, let’s just say you might want to start polishing your resume.

Read More

2026-02-23 21:13